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Abstract 30 
Context Maternal body mass index (BMI) is associated with increased birth weight 31 
but does not explain all the variance in fetal adiposity.  32 
Objective To assess the contribution of maternal body fat distribution to offspring 33 
birth weight and adiposity.  34 
Design Longitudinal study throughout gestation and at delivery. 35 
Setting Women recruited at 12 weeks of gestation and followed up at 26 and 36 36 
weeks. Cord blood was collected at delivery. 37 
Patients Pregnant women (n=45) with BMI 18.0-46.3 kg/m2 and healthy pregnancy 38 
outcome.  39 
Methods Maternal first trimester abdominal subcutaneous and visceral adipose 40 
tissue thickness (SAT and VAT) was assessed by ultrasound.  41 
Main outcome measures Maternal body fat distribution, maternal and cord plasma 42 
glucose and lipid concentrations, placental weight, birth weight and fetal adiposity 43 
assessed by cord blood leptin. 44 
Results VAT was the only anthropometric measure independently associated with 45 
birth weight centile (r2 adjusted 15.8%, P=0.002). BMI was associated with trimester 46 
2 and trimester 1 – 3 area under the curve (AUC) glucose and insulin resistance 47 
(HOMA).  SAT alone predicted trimester 2 lipoprotein lipase (LPL) mass (a marker of 48 
adipocyte insulin sensitivity) (11.3%, P=0.017). VAT was associated with fetal 49 
triglyceride (9.3%, P=0.047).  Placental weight was the only independent predictor of 50 
fetal adiposity (48%, P<0.001). Maternal trimester 2 and AUC LPL were inversely 51 
associated with fetal adiposity (r=-0.69, P=0.001 and r=-0.58, P=0.006 respectively).  52 
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Conclusions Maternal VAT provides additional information to BMI for prediction of 53 
birth weight. VAT may be a marker of reduced SAT expansion and increased 54 
availability of maternal fatty acids for placental transport.  55 
 56 
Precis 57 
In pregnant women with a healthy pregnancy outcome, first trimester visceral 58 
adipose tissue predicted birthweight centile possibly due to increased delivery of 59 
fatty acids to the placenta.  60 
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Introduction 61 
Maternal obesity occurs in around 20% of the UK antenatal population (1) and is 62 
associated with an increased risk of adverse pregnancy outcome (2) including the 63 
metabolic diseases of pregnancy, gestational diabetes mellitus (GDM) and pre-64 
eclampsia. Maternal obesity is also associated with offspring obesity, both at birth 65 
and in later life (3). Studies show that maternal pre-pregnancy total body fat predicts 66 
birth weight, though it is unclear to what extent this is explained by fetal somatic 67 
growth or fetal accumulation of fat (4). There is increasing concern about the impact 68 
of maternal BMI on the long term metabolic health of the fetus (5). 69 
 70 
Maternal obesity is associated with maternal insulin resistance (6) and metabolic 71 
dysfunction (7,8). GDM is defined by maternal hyperglycaemia and the associated 72 
fetal macrosomia may be explained by increased placental transport of glucose 73 
leading to increased fetal insulin secretion and hence increased growth, as described 74 
by Pedersen (9). This observation has now been extended to glucose tolerant 75 
mothers, as in the Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) trial, 76 
which highlighted the importance of maternal plasma glucose concentrations for 77 
increased birth weight and adiposity in the offspring (5). However, plasma glucose 78 
concentration did not explain all the variance in offspring adiposity, with residual 79 
contributions coming from maternal pre-pregnancy BMI and gestational weight gain 80 
(10-12). Furthermore, increased birth weight is observed even in GDM pregnancies 81 
in which plasma glucose is well-controlled (10,13,14).  82 
 83 
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There is evidence to suggest that high maternal fat mass and insulin resistance may 84 
expose the fetus to fuels other than glucose that could contribute to higher birth 85 
weight (13,15-17). Maternal hypertriglyceridaemia is a key element of maternal 86 
obesity and insulin resistance (7,8). Whole body lipolysis is increased in the third 87 
trimester of pregnancy (18) and is associated with maternal fat mass and estimated 88 
fetal weight (19). Maternal plasma triglyceride and free fatty acid also correlate with 89 
birth weight and measures of neonatal adiposity in GDM and in women screened for 90 
GDM with normal glucose tolerance (20-22). However, it is not clear if  these 91 
relationships exist in healthy non-obese pregnancy, to what extent they are 92 
independent of maternal body weight, and whether measures of maternal body fat 93 
distribution may be superior predictors of fetal birth weight and/or adiposity (23).  94 
 95 
Obesity, as defined by BMI in excess of 30, is a universally accepted measure of body 96 
fatness, but BMI conveys no information about the quantity, quality, location or 97 
metabolic function of discrete fat depots. BMI is a relatively weak proxy for 98 
discriminating metabolic dysfunction and cardio-metabolic risk in comparison to 99 
central obesity, especially when the latter is distinguished by high intra-abdominal 100 
visceral adipose tissue (VAT)(24).  BMI is unable to distinguish between individuals 101 
(pregnant or non-pregnant) who store fat as relatively benign subcutaneous adipose 102 
tissue (SAT) or as VAT, which is intimately associated with insulin resistance, 103 
hyperglycaemia, hypertriglyceridaemia, metabolic dysfunction and pathology (25-104 
27).  None of the above studies that related maternal adiposity to offspring 105 
birthweight and adiposity assessed body fat distribution. 106 
 107 
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In studies of pregnancy that did assess body fat distribution, pre-peritoneal and 108 
visceral fat were shown to increase during gestation, while SAT declined (28-32). 109 
Measures of VAT strongly predict metabolic complications of pregnancy, GDM 110 
(33,34) and pre-eclampsia (35,36), but it is not clear to what extent VAT is directly 111 
related to insulin resistance and increased plasma lipids and glucose in pregnancy 112 
(33,37-42). While VAT, measured by ultrasound between 12 and 20 weeks of 113 
gestation, is associated with fetal growth in overweight and obese women in the first 114 
trimester (43), with fetal growth and adiposity in the second trimester (44), and 115 
birthweight (45), the impact of abdominal SAT thickness on these measures has been 116 
largely overlooked. SAT thickness is correlated with first trimester fetal growth, but 117 
less so than VAT (43). SAT has also been found to be predictive (46-48) and non-118 
predictive of GDM (49), and is also less strongly associated with metabolic risk 119 
factors in pregnancy than VAT (37). 120 
 121 
The aim of this study was to assess the contribution of maternal body fat distribution 122 
to offspring birth weight and maternal and fetal insulin resistance in order to 123 
advance our understanding of the consequences of maternal obesity. Maternal first 124 
trimester measures of adiposity including BMI, VAT, abdominal SAT and hip 125 
circumference (a biomarker of lower body SAT) were assessed as predictors of birth 126 
weight, adiposity and metabolic dysfunction in neonates of healthy pregnant 127 
women. We also determined if any relationship could be explained by the influence 128 
of these fat depots on maternal glucose and lipid metabolism or placental weight.   129 
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Methods 130 
 131 
Longitudinal Study of Pregnancy 132 
Sixty women registered for obstetric care at the Princess Royal Maternity Unit, 133 
Glasgow, who were healthy and normotensive with no significant past medical 134 
history were recruited and followed prospectively throughout pregnancy. This study 135 
was initially designed to assess the impact of maternal obesity on microvascular 136 
function and powered for that outcome (50). Seven women were excluded from the 137 
final analysis; three delivered pre-term, two were excluded because of missing birth 138 
weight data, one had a miscarriage, and one had a baby with diGeorge syndrome.  139 
All remaining women had no pregnancy-related complications. Baseline data and 140 
complete longitudinal data were available for 53 and 45 women, respectively.  The 141 
study was performed according to the Declaration of Helsinki, approval was granted 142 
by the Research Ethics Committee of North Glasgow University NHS Trust, and each 143 
subject gave written informed consent. The women attended after an overnight fast 144 
(>10 hours). Blood samples were collected at a mean of 12.4 (range 8–14) [T1], 26.1 145 
(24–28) [T2] and 35.5 (33–38) [T3] weeks of gestation. The characteristics of the 146 
patients were recorded at the first antenatal hospital appointment and delivery 147 
details from patient notes. Customised birth weight centiles were calculated using 148 
the Gestation Network Centile Calculator 5.4 149 
(http://www.gestation.net/birthweight_centiles/centile_online.htm). Deprivation 150 
category (DEPCAT score), a measure of socioeconomic status, was assigned using the 151 
Scottish Area Deprivation Index for Scottish postcode sectors, 1998 (51). Placental 152 
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tissue and fetal cord blood was collected at delivery from a subgroup of these 153 
pregnancies (n=23, 42%). 154 
 155 
Baseline anthropometric and fat thickness measurements 156 
At the first antenatal appointment (mean 12.4 weeks of gestation), patient height, 157 
weight, waist circumference and hip circumference were measured. Waist 158 
circumference was measured at the level of the umbilicus. Hip circumference was 159 
measured at the widest point over the buttocks. Waist and hip circumference were 160 
measured in duplicate to the nearest 0.5 cm. If the difference between the two 161 
measurements was greater than 2 cm, a third measurement was taken and the mean 162 
of the two closest measurements was calculated. All measurements were taken by 163 
the same examiner. Body mass index (BMI) was calculated as booking weight (kg), 164 
divided by height (m) squared.  Baseline upper body abdominal SAT and upper body 165 
VAT thickness was assessed by ultrasound (52). Measurements were taken 2cm 166 
below the xiphisternum and the abdominal probe was placed on the skin with 167 
minimal pressure. Abdominal SAT was measured as the thickness between the 168 
inferior border of the dermal layer and the rectus abdominus sheath at the level of 169 
the umbilicus. Visceral fat was taken as the vertical measurement between the 170 
rectus sheath and the aorta at the umbilicus. Three consecutive measurements in 171 
millimetres were taken and an average reading was calculated. All measures were 172 
made by the same operator (F.S.) on the same machine. 173 
 174 
Blood parameters 175 
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Glucose assays (53) were performed by Clinical Biochemistry, Glasgow Royal 176 
Infirmary and plasma total cholesterol, HDL cholesterol and total triglyceride 177 
concentrations were determined as described previously (7). Insulin (Mercodia) and 178 
leptin (R & D Systems) analyses were performed by ELISA according to the 179 
manufacturer’s instructions. LPL mass was determined by ELISA using bovine LPL as 180 
standard (54,55). HOMA was calculated as [fasting insulin (mU/L) x fasting glucose 181 
(mmol/L)]/22.5]. Erythrocyte membrane phospholipid fatty acid composition was 182 
measured as previously described (56), and the ratio of 16:0/18:2 n-6 was used as an 183 
index of de novo lipogenesis (57,58). 184 
 185 
Statistical analysis 186 
Continuous variables are represented as means (standard deviation), categorical 187 
variables as number and percentage. Total area under the time (T1 to T3 weeks’ 188 
gestation) x concentration curve (AUC) were calculated using the trapezium method 189 
(59). Normality testing was carried out using the Ryan-Joiner test and data was log or 190 
square root transformed to achieve a normal distribution as necessary. Associations 191 
between variables were examined by Pearson’s correlation analysis. Two measures 192 
of gestational fuel exposure were used. Firstly, the total area under the trimester 1 193 
to trimester 3 maternal glucose, and triglyceride concentration and HOMA curves 194 
were calculated to assess total gestational exposure. Secondly, because the 195 
univariate associations between maternal anthropometrics and maternal plasma 196 
triglyceride, glucose and HOMA were the strongest and notably distinct in trimester 197 
2 (Supplemental Figure 1), trimester 2 data were selected for further study.  198 
Stepwise regression analysis, a method of fitting regression models in which the 199 
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choice of predictive variables and simultaneous removal of unimportant variables is 200 
carried out by an automatic procedure, was used to test associations between 201 
maternal anthropometrics and maternal or fetal blood glucose and lipids and the 202 
influence of confounding variables such as placental weight, using P-to-enter and P-203 
to-stay P<0.15. All statistical analysis was carried out in Minitab Vs18.   204 
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Results 205 
Maternal characteristics 206 
Demographic data for all women with first trimester measurements are shown in 207 
Table 1. Women were on average 28 years of age, had a mean body mass index 208 
(BMI) of 28 kg/m2; just over one third were currently smoking during their pregnancy 209 
and just less than one half were in their first pregnancy. More than half the women 210 
were classed as having deprived social status. The women had normal antenatal 211 
appointment blood pressure, had no pregnancy-related complications and all 212 
delivered healthy babies at term. The demographic characteristics of the subgroup, 213 
where repeated longitudinal measures were available, were similar to the total 214 
group (Table 1). 215 
 216 
Relationship between maternal anthropometrics and offspring birth weight centile 217 
and placental weight 218 
Maternal BMI is a recognised predictor of offspring birthweight. To test whether 219 
other, more specific, measures of maternal adiposity might be better predictors of 220 
offspring birth weight, univariate correlation between maternal anthropometric 221 
measures and birth weight centile, birth weight and placental weight were first 222 
assessed. Birth weight centile was associated with maternal BMI (r=0.41, P=0.002), 223 
waist circumference (r=0.42, P=0.003), hip circumference (r=0.32, P=0.021), SAT 224 
thickness (r=0.34, P=0.012), VAT thickness (r=0.41, P=0.003) and SAT plus VAT 225 
thickness (r=0.39, P=0.004), but not waist-hip ratio (r= 0.16, P=0.25) or VAT/SAT ratio 226 
(r=0.01, P=0.97). No maternal anthropometric measures were associated with birth 227 
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weight alone, and only maternal BMI was weakly associated with placental weight 228 
(r=0.27, P=0.047).  229 
To examine possible multivariable associations between maternal anthropometrics 230 
and birth weight centile, the former was entered into a stepwise regression model (P 231 
to enter and P to stay 0.15).  VAT was the only anthropometric measure significantly 232 
associated with birth weight centile (r2 adjusted 15.8%, P=0.002, Figure 1). A one mm 233 
increase in VAT thickness resulted in a 2.26 centile increase in birthweight centile. A 234 
VAT thickness of up to 10mm was associated with the 43rd (unadjusted) and 38th 235 
(after adjustment for BMI, waist circumference, hip circumference, SAT thickness 236 
and SAT plus VAT thickness) birth weight centile. Above 10mm VAT, birth weight 237 
centiles were between the 70th and 80th centile. While inclusion of placental weight 238 
in the regression model attenuated the relationship between VAT and birth weight 239 
centile, it remained significant [r2 adjusted 11.8%, P=0.006; birth weight centile = -240 
12.3 + 1.891 VAT (mm) + 0.0630 placental weight (g)] suggesting an independent 241 
association between VAT thickness and birth weight centile. Placental weight was 242 
significantly associated with birth weight centile in this model (r2 adjusted 12.1%, 243 
P=0.005), suggesting that placental weight also has an independent contribution to 244 
birth weight equivalent to that of VAT thickness. 245 
 246 
Relationships between maternal anthropometrics and fetal cord plasma glucose and 247 
lipids  248 
In a univariate analysis maternal VAT thickness was significantly correlated (P<0.05) 249 
with fetal cord plasma total cholesterol, triglyceride, non-esterified fatty acids and 250 
negatively with a marker of insulin resistance (HOMA), but there was no relationship 251 
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with fetal cord plasma HDL cholesterol, glucose or insulin (Table 2). Maternal SAT 252 
thickness correlated significantly with cord plasma total cholesterol. There was no 253 
relationship between maternal BMI or hip circumference and cord plasma glucose or 254 
lipids. On multivariate regression analysis, VAT showed significant independent 255 
associations with cord plasma triglyceride, non-esterified fatty acids and cholesterol, 256 
while BMI showed significant negative independent associations with cord plasma 257 
insulin and HOMA (Table 2). After inclusion of mode of delivery in the model, the 258 
associations between maternal BMI and cord plasma insulin and HOMA and 259 
between VAT and cord plasma triglyceride persisted and now hip circumference was 260 
positively associated with cord plasma cholesterol (Table 2). The inclusion of 261 
placental weight in the regression model had no impact on the associations between 262 
BMI and cord plasma HOMA, VAT thickness and cord plasma triglyceride or between 263 
hip circumference and cord plasma cholesterol maternal BMI and HOMA.  The 264 
inclusion of placental weight strengthened the negative association between BMI 265 
and cord blood insulin (r2 adjusted 31%, P=0.009).   266 
 267 
Relationship between maternal anthropometrics and maternal plasma glucose and 268 
lipids  269 
Maternal BMI was correlated significantly (P<0.05) with maternal trimester 2 and 270 
AUC glucose and trimester 2 and AUC HOMA (Table 3). SAT thickness was correlated 271 
significantly with maternal trimester 2 HOMA only. VAT thickness was correlated 272 
with maternal trimester 2 glucose and HOMA. Hip circumference was correlated 273 
with maternal AUC glucose and trimester 2 and AUC HOMA.  On stepwise regression, 274 
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only maternal BMI remained significantly associated with both maternal trimester 2 275 
and AUC glucose and HOMA (Table 3).  276 
 277 
Relationships between maternal plasma glucose and lipid exposure and fetal cord 278 
plasma glucose and lipids, fetal adiposity (cord plasma leptin) and birth weight 279 
centile  280 
None of the markers of maternal glucose or lipid gestational exposure were 281 
associated with any measure of cord plasma glucose or lipid metabolism or fetal 282 
adiposity before or after accounting for mode of delivery other than maternal AUC 283 
triglyceride (r2 = 20%, P=0.020, coefficient = -0.007) and maternal AUC HOMA 284 
(r2=15%, P=0.042, coefficient = 0.255) which were associated with cord plasma HDL 285 
after accounting for mode of delivery. Maternal trimester 2 HOMA (r=0.33, P=0.028) 286 
and AUC glucose (r=0.36, P=0.016) were univariately associated with birthweight 287 
centile. T2 HOMA (P=0.046) and placental weight (P<0.001) remained as predictors 288 
of birthweight centile in a minimal model that included these two variables and AUC 289 
glucose (r2 adjusted =31.7%).  290 
 291 
Maternal anthropometric measures and fetal adiposity  292 
Fetal adiposity was not associated with maternal BMI, SAT or VAT thickness or hip 293 
circumference in multivariate analysis. However, there was a significant positive 294 
association between placental weight and cord plasma leptin (r2=57%, P<0.001). A 295 
multivariable model including maternal anthropometrics, placental weight and mode 296 
of delivery showed that only placental weight was independently associated with 297 
fetal adiposity (r2 adjusted 48%, P<0.001). There was no association between cord 298 
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plasma triglyceride or non-esterified fatty acids and fetal adiposity even after 299 
adjusting for mode of delivery. The 16:0/18:2 n-6 ratio of fetal erythrocyte fatty acids 300 
was used as an index of de novo lipogenesis. This index was unrelated to fetal 301 
adiposity (r=-0.13, P=0.57), but inversely associated with fetal cord plasma 302 
triglyceride (r=-0.44, P=0.044) (Supplemental Figure 2), an effect lost after 303 
accounting for mode of delivery. 304 
 305 
Maternal lipoprotein lipase (LPL) mass, maternal and fetal plasma glucose and lipids, 306 
fetal adiposity and birth weight centile  307 
Low LPL mass is a marker of severity of metabolic syndrome and low plasma levels 308 
reflect reduced LPL synthesis by adipocytes in the insulin resistant state. Maternal 309 
trimester 2 LPL mass was negatively correlated with maternal BMI (r=-0.36, P=0.017) 310 
and SAT (r=-0.36, P=0.018) while AUC LPL mass correlated with SAT (r=-0.30, 311 
P=0.048). In a multivariate regression model including all maternal anthropometrics, 312 
maternal SAT alone predicted trimester 2 LPL mass (r2 adjusted 11.3%, P=0.017).  313 
Maternal trimester 2 or AUC LPL mass was not correlated with cord plasma glucose 314 
or lipid levels. Maternal trimester 2 LPL was negatively correlated with maternal 315 
trimester 2 glucose (r=-0.30, P=0.049), AUC glucose (r=-0.36, P=0.019) and trimester 316 
2 HOMA (-0.30, P=0.048). In particular, maternal trimester 2 and AUC LPL mass were 317 
strongly correlated with maternal trimester 2 triglycerides (r=-0.52, P=0.001 and r=-318 
0.55, P<0.001 respectively) and AUC triglycerides (r=-0.41, P=0.007 and r=-0.41, 319 
P=0.006 respectively). Maternal trimester 2 and AUC LPL were not associated with 320 
birth weight centile but both were strongly associated with fetal leptin (r=-0.69, 321 
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P=0.001 and r=-0.58, P=0.006 respectively) (Figure 2) and these associations were 322 
independent of mode of delivery.  323 
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Discussion 324 
Maternal first trimester VAT thickness on ultrasound, but not first trimester BMI, 325 
abdominal SAT or hip circumference, was independently associated with birth 326 
weight centile. This observation is in agreement with a similar study in adolescent 327 
mothers, although the previous study lacked SAT assessment (45). The strength of 328 
associations in the current study were of greater magnitude than that previously 329 
reported, possibly due to our older, more obese population. Maternal VAT was also 330 
associated with fetal cord plasma triglyceride although this variable was not related 331 
to birth weight centile or fetal adiposity. Maternal VAT was not associated with 332 
maternal plasma lipids, as might be expected from data in non-pregnant women, in 333 
which an oversupply of fatty acids in the portal circulation to the liver can drive an 334 
increased  synthesis and secretion of VLDL (60). This lack of relationship between 335 
maternal VAT and plasma triglyceride suggests that VAT-associated 336 
hypertriglyceridaemia may be superseded by maternal metabolic adaptation to 337 
pregnancy.  338 
 339 
We have previously shown in ex vivo adipocyte lipolysis experiments, that SAT 340 
adipocytes have higher lipolysis rates than VAT adipocytes in pregnancy (61). Thus, in 341 
healthy pregnancy, SAT rather than VAT is the primary source of the maternal fatty 342 
acids released for maternal metabolism and placental transport, secondary to 343 
pregnancy hormone induced gestational insulin resistance (61).  A slowing or 344 
reversal of maternal (subcutaneous) adipose tissue accumulation towards the end of 345 
the second trimester coincides with the accelerated phase of fetal adipose tissue 346 
accretion (14).  In pregnancy, it is possible that VAT is a marker of ectopic fat 347 
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accumulation rather than a direct source of lipids for transport to the fetus. In non-348 
pregnant individuals, fat accumulation in VAT and ectopically in other organs is 349 
secondary to dysregulated adipocyte expansion in subcutaneous fat (24,62,63). Fatty 350 
acids that overspill from the SAT compartment accumulate in VAT and are stored 351 
ectopically as intracellular lipid droplets in other tissues such as the liver and 352 
pancreas. However, in pregnancy, the overspill fatty acids from SAT could also be 353 
available for uptake and transport by the placenta, thus increasing lipid supply to the 354 
fetus (Figure 3).  355 
 356 
Low maternal LPL mass is a measure of metabolic syndrome severity and probably 357 
reflects a reduced rate of LPL synthesis by insulin resistant SAT adipocytes (7,64-66). 358 
In the present study, LPL mass was inversely associated with maternal plasma 359 
triglyceride and fetal adiposity, supporting the idea of a failure of SAT adipocyte 360 
expansion and the development of adipocyte insulin resistance with a consequent 361 
overspill of fatty acids and transport to the fetus (Figure 3). Potential mechanisms for 362 
increased fetal adiposity include an increased lipid supply across the placenta or 363 
increased de novo lipogenesis from glucose supplied across the placenta. The inverse 364 
association between cord plasma triglyceride and an index of fetal de novo 365 
lipogenesis was not independent of mode of delivery, and in any case would suggest 366 
that the transported fatty acids may be utilised by the fetus in preference to the de 367 
novo synthesis of fatty acids. Failure of SAT adipocyte expansion has been proposed 368 
to underlie obesity-related pre-eclampsia (61) and gestational diabetes mellitus 369 
(67,68). In the healthy women under study here, the maximum VAT thickness 370 
measured was 27.3mm which may represent a propensity towards limited SAT 371 
20 
 
expansion rather than a pathological state, especially when it is considered that pre-372 
eclampsia and GDM are predicted by VAT thickness above 52mm (36) and 47.4mm 373 
(33) respectively. 374 
 375 
Maternal placental weight had an independent association with birth weight centile 376 
in this cohort of women. Maternal body mass index was related to both placental 377 
weight and maternal insulin resistance, and through these associations may be 378 
indirectly linked to birth weight centile and fetal adiposity. Our data showed that 379 
trimester 2 markers of glucose metabolism were most strongly related to maternal 380 
anthropometrics. The middle trimester is the time of greatest acceleration in fetal 381 
growth (69), when changes in maternal metabolism would be expected to have most 382 
impact on birthweight centile. Maternal gestational insulin resistance directs more 383 
glucose for transport to the fetus. A combination of higher placental weight, 384 
increased surface area for transport of nutrients, and raised trimester 2 plasma 385 
glucose may explain the link between BMI and fetal birth weight centile and 386 
adiposity. Interestingly, maternal BMI was associated with reduced fetal cord blood 387 
insulin and HOMA suggesting that fetuses of healthy high BMI mothers are more 388 
insulin sensitive and hence efficient at storing fuel as adipose tissue in addition to 389 
having more insulin-induced somatic growth. It is not clear whether fetal insulin 390 
sensitivity is directly influenced by the mother or is a fetal response to the 391 
availability of fuel.  392 
 393 
The data presented here suggest an input from both glucose and lipids into birth 394 
weight and fetal adiposity. While there is plentiful evidence to link maternal plasma 395 
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glucose levels with fetal growth, there has been less research into the role of plasma 396 
lipids. Lipid concentrations are equally regulated by insulin and affected by insulin 397 
resistance. It is notable that a stable isotope tracer study in healthy women at 34-36 398 
weeks of gestation showed that both glucose production rate and lipolysis were 399 
independently correlated with estimated fetal size on ultrasound scan (19). Our data 400 
also suggest that glucose and lipid metabolism are intertwined and influenced by 401 
both maternal adiposity and body fat distribution. 402 
 403 
This study had a number of strengths including its prospective design and the 404 
assessment of a number of maternal anthropometrics in parallel with measures of 405 
both maternal and fetal cord glucose and lipid metabolism. Limitations include a lack 406 
of kinetic assessment of maternal and fetal metabolites and the use of steady state 407 
concentrations to infer such fluxes. Our conclusions with respect to fetal adiposity 408 
are limited by cord blood samples being collected in less than half of the cohort, in 409 
which plasma leptin concentration was measured as a surrogate. 410 
 411 
In summary, maternal body fat distribution in healthy pregnancy, as identified by 412 
VAT thickness, provides additional information to that of maternal BMI in the 413 
prediction of birth weight centile. VAT may be acting as a marker of reduced SAT 414 
expansion, leading to increased availability of plasma fatty acids for placental 415 
transport.   416 
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Data availability 417 
The datasets generated during and analysed during the current study are not 418 
publically available but are available from the corresponding author on reasonable 419 
request.  420 
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Table 1. Maternal antenatal booking characteristics. Values are mean and standard 672 
deviation (SD) for continuous variables or number (%) for categorical variables. †n=1 missing 673 
data. 674 
 Baseline data 
n=53 
Longitudinal data 
n=45 
Booking visit   
Age (years) 28.3 (5.1) 28.6 (5.0) 
Smokers (number (%)) 19 (35.8) 16 (35.6) 
Deprivation Index  
DEPCAT Score (number (%)) 
Affluent (1-2) 
Intermediate (3-5) 
Deprived (6-7) 
 
 
5 (9.4) 
18 (34.0) 
30 (56.6) 
 
 
5 (11.1) 
16 (35.6) 
24 (53.3) 
Primiparous 25 (47.2) 21 (46.7) 
Systolic Blood Pressure (mmHg)  118 (13) 119 (11) 
Diastolic Blood Pressure (mmHg)  68 (9) 69 (9) 
BMI (kg/m2) 28.4 (6.0) 28.1 (5.7) 
BMI range (kg/m2) 18.0 – 46.3 18.0 – 46.3 
Waist circumference (cm) 89.5 (14.8) 89.5 (14.8) 
Hip circumference (cm) † 107 (15) 108 (15) 
Waist/Hip ratio 0.83 (0.08) 0.84 (0.08) 
Visceral fat thickness (mm) 13.4 (5.6) 13.2 (5.5) 
Subcutaneous fat thickness (mm) 25.1 (11.4) 24.5 (10.9) 
Visceral/Subcutaneous fat thickness 0.58 (0.23) 0.58 (0.24) 
Visceral plus subcutaneous fat 
thickness (mm) 
38.4 (15.7) 37.7 (15.1) 
At delivery   
Gestation at delivery (days) 279 (9) 281 (7) 
Fetal sex, number (%) male 29 (55) 24 (53) 
Placental weight (g)  763 (175) 785 (175) 
Birth weight (g)  3606 (555) 3680 (560) 
Birth Weight Centile 61 (31) 62 (31) 
  675 
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Table 2 Maternal BMI, VAT thickness, SAT thickness and hip circumference association with fetal cord plasma markers of glucose and lipid metabolism 676 
Mean (standard deviation) cord plasma levels (n=23) of each parameter are shown below along with their univariate association (Pearson’s correlation) 677 
with maternal BMI, VAT and SAT thickness and hip circumference. The relationship between maternal BMI, VAT and SAT thickness and fetal cord plasma 678 
metabolic measures was determined by entering BMI, SAT, VAT and hip circumference in a stepwise regression model P to enter and P to stay 0.15. Mode 679 
of delivery (MOD) [assisted (A), elective Caesarean section (L), emergency Caesarean section (M) and vaginal (V) delivery] was added to the models as a 680 
confounding variable. NEFA = non-esterified fatty acid.  r2 adjusted and P values are stated. *analysis carried out on log-transformed data. † P<0.05, ‡ no 681 
terms were at P<0.15 to be entered into the model.  682 
Response Cord plasma 
mean (SD) 
Obesity 
measure 
Univariate 
correlation 
 
Coefficient Contribution 
to variance, 
multivariable 
P Contribution 
to variance, 
multivariable 
including 
MOD 
P 
Glucose 
(mmol/L) 
4.30 (1.07) BMI 
SAT 
VAT 
Hip 
-0.17 
-0.07 
-0.34 
0.08 
-0.0655 VAT 6.9% 0.013 No model‡ - 
Insulin* 
(mU/L) 
6.56 (6.64) BMI 
SAT 
VAT 
Hip 
-0.36 
-0.37 
-0.37 
-0.36 
-0.0332 BMI 15.4% 0.040 BMI 15.4% 0.040 
HOMA-IR* 1.29 (1.21) BMI -0.38 -0.0596 BMI 20.5% 0.023 BMI 20.5% 0.023 
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Response Cord plasma 
mean (SD) 
Obesity 
measure 
Univariate 
correlation 
 
Coefficient Contribution 
to variance, 
multivariable 
P Contribution 
to variance, 
multivariable 
including 
MOD 
P 
 SAT 
VAT 
Hip 
-0.35 
-0.45† 
-0.28 
Triglyceride 
(mmol/L)* 
0.72 (0.65) BMI 
SAT 
VAT 
Hip 
0.16 
0.30 
0.42† 
0.14 
0.01994 VAT 14.8%  0.043 VAT 9.3%  0.047 
NEFA* 
(mmol/L) 
0.19 (0.12) BMI 
SAT 
VAT 
Hip 
0.26 
0.26 
0.47† 
0.28 
0.0236 VAT 17.5% 0.034 VAT 12.8% 0.075 
Total 
cholesterol* 
(mmol/L) 
1.79 (0.65) BMI 
SAT 
VAT 
Hip 
0.33 
0.42† 
0.43† 
0.33 
0.00938 VAT 14.0% 0.049 Hip 16.8% 0.002 
HDL 
cholesterol 
(mmol/L) 
0.74 (0.18) BMI 
SAT 
VAT 
Hip 
0.12 
0.02 
-0.11 
0.15 
 No model‡  - - 
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Table 3 Maternal BMI, abdominal visceral and subcutaneous adipose tissue and hip 684 
circumference associations with maternal markers of gestational fuel exposure Mean 685 
(standard deviation) maternal plasma trimester 2 levels or AUC trimester 1 to trimester 3 686 
(n=45) are shown below along with their univariate association (Pearson’s correlation) with 687 
maternal BMI, VAT and SAT thickness and hip circumference.  688 
The relationship between maternal BMI, visceral adipose tissue (VAT) and upper body 689 
subcutaneous adipose tissue (SAT) thickness and maternal plasma metabolic measures was 690 
determined by entering BMI, SAT, VAT and hip circumference in a stepwise regression model 691 
P to enter and P to stay 0.15. r2 adjusted and P values are stated. *analysis carried out on 692 
log-transformed data. † P<0.05, ‡ no terms were at P<0.15 to be entered into the model.  693 
Response Maternal 
plasma   
mean (SD) 
Obesity 
measure 
Univariate 
correlation 
 
Coefficient Contribution 
to variance, 
multivariable 
P 
Maternal T2 
Glucose 
(mmol/L)* 
5.41 (1.17) BMI 
SAT 
VAT 
Hip 
0.38† 
0.20 
0.32† 
0.28 
0.00591 BMI 12.5% 0.011 
Maternal T2 
Triglyceride 
(mmol/L)* 
2.41 (0.73) BMI 
SAT 
VAT 
Hip 
0.20 
0.27 
0.17 
0.12 
0.00348 SAT 5.1% 0.078 
Maternal T2 
HOMA* 
 
12.3 (10.8) BMI 
SAT 
VAT 
Hip 
0.41† 
0.31† 
0.37† 
0.33† 
0.0313 BMI 15.1% 0.005 
Maternal 
AUC glucose 
(mmol/l x 
weeks)* 
120 (26) BMI 
SAT 
VAT 
Hip 
0.39† 
0.17 
0.27 
0.34† 
0.00563 BMI 15.3% 0.009 
Maternal 
AUC 
triglyceride 
(mmol/L x 
weeks) 
50 (14) BMI 
SAT 
VAT 
Hip 
0.18 
0.27 
0.06 
0.15 
 No model‡  
Maternal 
AUC HOMA 
(HOMAx 
240 (186) BMI 
SAT 
VAT 
0.35† 
0.25 
0.24 
0.02074 BMI 10.0% 0.021 
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Response Maternal 
plasma   
mean (SD) 
Obesity 
measure 
Univariate 
correlation 
 
Coefficient Contribution 
to variance, 
multivariable 
P 
weeks)* Hip 0.31† 
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Legends for figures and tables 695 
 696 
Figure 1. Offspring birth weight centile by VAT thickness: 0-10mm [n=19, mean 697 
(standard deviation) 7.5 (2.0) mm], 10-20mm [n=27, 15.0 (2.6) mm], 20-30mm [n=7, 698 
22.9 (2.9) mm]. Means and 95% confidence interval for the mean are plotted for 699 
unadjusted data and data adjusted for other anthropometric measures in a stepwise 700 
regression (BMI, waist circumference, hip circumference, SAT thickness, SAT plus 701 
VAT thickness). 702 
 703 
Figure 2. Association between fetal adiposity (cord plasma leptin) and maternal 704 
trimester 2 lipoprotein lipase mass. Univariate correlation (Pearson’s) between 705 
maternal trimester 2 lipoprotein lipase mass and fetal adiposity r=-0.69 P=0 .001 706 
(n=2 data missing). 707 
 708 
Figure 3. Proposed pathway for the contribution of maternal BMI, SAT and VAT to 709 
fetal birth weight and adiposity. In low BMI pregnant women subcutaneous adipose 710 
tissue (SAT) contains insulin sensitive (IS), hyperplasic adipocytes secreting large 711 
amounts of lipoprotein lipase (LPL) that are capable of expanding to store excess 712 
fatty acids (NEFA). In an insulin sensitive environment, this facilitates regulation of 713 
maternal glucose and triglyceride concentrations providing sufficient fuels for 714 
placental transport to support healthy fetal growth. In high BMI pregnant women, 715 
SAT contains insulin resistant (IR), hypertrophic adipocytes resulting from limited 716 
expansion of pre-adipocytes to form mature adipocytes. SAT has a reduced ability to 717 
store fatty acid which spill over and are directed to the liver increasing plasma 718 
triglyceride (TG) concentrations and are stored ectopically in visceral adipose tissue 719 
(VAT). The increasingly insulin resistance environment also raises plasma glucose 720 
levels thus increasing the supply of both fuels across a larger placenta resulting in a 721 
larger and fatter fetus.  722 
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Supplemental Material 731 
Supplemental Figures 732 
Supplemental Figure 1.  Glucose, triglyceride and HOMA by trimester according to 733 
BMI, VAT thickness, SAT thickness and hip circumference. Univariate associations 734 
between maternal anthropometric measures and maternal plasma glucose (A) and 735 
triglyceride (B) concentration, and maternal HOMA (C) are shown. 736 
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Supplemental Figure 2. Association between fetal de novo lipogenesis and cord 744 
blood triglyceride concentrations. Univariate correlation (Pearson’s) between cord 745 
blood triglyceride concentration (log) and an index of fetal de novo lipogenesis 746 
(erythrocyte 16:0/18:2 n-6; n=2 data missing) r=-0.44 P=0.044. 747 
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